• Dr. Jackie Fouse to step down as Executive Chair of Dermavant

• Dr. Frank Torti named Chairman of the Board, and Myrtle Potter also joins board of directors

• Dermavant prepares Phase…

Mr. Allouche has over 20 years of combined experience in finance leadership, audit, and advisory roles, most recently serving as Principal Accounting Officer, Head of Finance, and Corporate Controller at Revance Therapeutics Dermavant plans to initiate Phase 3 clinical program for tapinarof in second quarter of 2019 United States Patent and Trademark Office (USPTO) issues […]

Former Chief Commercial Officer at Anacor and Medicis joins leadership team Mr. Ippolito has launched over 20 branded medicines in dermatology Dermavant has licensed its fourth investigational drug for the treatment of acne BASEL, Switzerland, September 29, 2017 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced […]

– Over 20 Years of Combined Experience in Global Finance Leadership, Audit, and Advisory Roles in the Biopharmaceutical Industry LONG BEACH, Calif., and BASEL, Switzerland, May 6, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of Michael Swartzburg as Chief Financial Officer. Mr. Swartzburg […]

Over 20 years of leadership experience in the biopharmaceutical industry Former Vice President and General Manager, U.S. Prescription Business for Galderma Former Head of Pfizer’s U.S. Pharmaceutical Contracting and Pricing Organization Dermavant expects Phase 3 data for tapinarof in 2020 LONG BEACH, Calif. and BASEL, Switzerland—Jan. 22, 2020—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, […]

LONDON—May 15, 2019—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to Dermavant’s Board of Directors. Mr. Nelson served as President and Chief Executive Officer, and member of the Board of Directors, of MAP Pharmaceuticals, Inc. from 2005 until its acquisition by Allergan […]

Dr. Brown previously served as Head of Global Pharmaceutical Development at Galderma and has over 25 years of experience leading clinical development programs Dermavant plans to initiate Phase 3 clinical program for tapinarof in first half of 2019 BASEL, Switzerland—Jan. 2, 2019—Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Philip M. […]

Dermavant Sciences Appoints Dr. Jacqualyn Fouse as Executive Chairman Dr. Fouse recently served as President and COO of Celgene Corp. and a member of Celgene’s Board of Directors Dr. Fouse joins growing network of industry leaders within the Roivant Sciences family of companies BASEL, Switzerland, July 10, 2017 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company […]